DE602004013283D1 - Diagnostisches verfahren der mastozytose - Google Patents

Diagnostisches verfahren der mastozytose

Info

Publication number
DE602004013283D1
DE602004013283D1 DE602004013283T DE602004013283T DE602004013283D1 DE 602004013283 D1 DE602004013283 D1 DE 602004013283D1 DE 602004013283 T DE602004013283 T DE 602004013283T DE 602004013283 T DE602004013283 T DE 602004013283T DE 602004013283 D1 DE602004013283 D1 DE 602004013283D1
Authority
DE
Germany
Prior art keywords
mutation
detected
masto
cytosis
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004013283T
Other languages
English (en)
Inventor
Jean-Pierre Kinet
Alain Moussy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of DE602004013283D1 publication Critical patent/DE602004013283D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004013283T 2003-02-27 2004-02-27 Diagnostisches verfahren der mastozytose Expired - Lifetime DE602004013283D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44986103P 2003-02-27 2003-02-27
PCT/IB2004/000907 WO2004076693A1 (en) 2003-02-27 2004-02-27 Tailored treatment suitable for different forms of mastocytosis

Publications (1)

Publication Number Publication Date
DE602004013283D1 true DE602004013283D1 (de) 2008-06-05

Family

ID=32927581

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013283T Expired - Lifetime DE602004013283D1 (de) 2003-02-27 2004-02-27 Diagnostisches verfahren der mastozytose

Country Status (7)

Country Link
US (1) US20080025916A1 (de)
EP (1) EP1597398B1 (de)
JP (1) JP2006519220A (de)
AT (1) ATE393243T1 (de)
CA (1) CA2517308A1 (de)
DE (1) DE602004013283D1 (de)
WO (1) WO2004076693A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653934B1 (de) * 2003-08-15 2008-05-14 AB Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
CA2542909C (en) 2003-10-23 2012-07-10 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
KR20080019578A (ko) * 2005-04-04 2008-03-04 에이비 사이언스 치환된 옥사졸 유도체 및 이의 티로신 키나제 억제제로서의용도
US8088806B2 (en) 2005-05-09 2012-01-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
NZ578944A (en) 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
CN101801964A (zh) 2007-05-22 2010-08-11 艾其林医药公司 杂芳基取代的噻唑及其作为抗病毒剂的用途
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1471907B1 (de) * 2001-06-29 2008-07-16 AB Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US20040266771A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of tyrosine kinase inhibitors for treating bone loss
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
CA2452171A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
DK1525200T3 (da) * 2002-08-02 2007-12-03 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoler til sygdomsbehandling

Also Published As

Publication number Publication date
EP1597398A1 (de) 2005-11-23
US20080025916A1 (en) 2008-01-31
ATE393243T1 (de) 2008-05-15
CA2517308A1 (en) 2004-09-10
EP1597398B1 (de) 2008-04-23
WO2004076693A1 (en) 2004-09-10
JP2006519220A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
Derks et al. Peri‐implantitis–onset and pattern of progression
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
ATE527010T1 (de) Vorrichtung zur verabreichung von co
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
WO2006041678A3 (en) Pharmaceutical treatment effectiveness analysis computer system and methods
DE60333631D1 (de) Verhaltensbasierte anpassung von computersystemen
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
ATE447878T1 (de) Verfahren und vorrichtung zur augenverfolgung
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
CY1110503T1 (el) Πενταμιδινη για θεραπεια καρκινου
ATE526029T1 (de) Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
ATE460166T1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
DK0949920T3 (da) Höjselektive butyrylcholinesteraseinhibitorer til behandling og diagnose af Alzheimers sygdom og demens
DE602004013283D1 (de) Diagnostisches verfahren der mastozytose
WO2005007144A3 (en) Method of diagnosis and treatment for asthma based on haplotype association
BR0206251A (pt) Métodos para avaliar e tratar leucemia
WO2003070700A3 (en) Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
ATE557087T1 (de) Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz
DE602004031356D1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
ATE212552T1 (de) Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
ATE376419T1 (de) Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
ATE548973T1 (de) Beurteilung kognitiver beeinträchtigung
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus

Legal Events

Date Code Title Description
8332 No legal effect for de